A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
World-first research by Monash University in Australia has been able to detect positive COVID-19 cases using blood samples in about 20 minutes, and identify whether someone has contracted the virus.
Since mRNAs play a key role in protein synthesis in vivo, the use of mRNAs as medicines and for in vitro protein synthesis has been desired.
The T cells, along with antibodies, are an integral part of the human immune response against viral infections due to their ability to directly target and kill infected cells.
An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine.
UK scientists declared recently that antibodies extracted from llamas have been demonstrated to neutralize the SARS-CoV-2 virus in laboratory tests.
University of Alabama at Birmingham researchers have added fresh evidence that early exposure to vaccine-, bacterial- or microbiota-derived antigens has a dramatic effect on the diversity of antibodies an adult mammal will have to fight future infections by pathogens.
A multidisciplinary team from The University of Texas Medical Branch at Galveston has uncovered a new mechanism for designing antiviral drugs for dengue virus. The study is currently available in Proceedings of the National Academy of Sciences.
International research collaboration to pioneer the field of immuno-cardiology and investigate ways to harness the power of the immune system to improve recovery from heart attacks will be led at the Perelman School of Medicine at the University of Pennsylvania by Jonathan Epstein, MD, executive vice dean, chief scientific officer and the William Wikoff Smith Professor of Cardiovascular Research.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has established a new clinical trial network that aims to enroll thousands of volunteers in large-scale clinical trials testing a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.
New immunotherapy developed by researchers at Northwestern University dramatically extends the survival time of mice with triple-negative breast cancer, one of the most aggressive and difficult-to-treat forms of breast cancer.
An adenovirus infection can be potentially life-threatening, especially for children after a stem cell transplant.
An analysis of nearly 300 recently identified human SARS-CoV-2 antibodies uncovered a gene frequently used in antibodies that most effectively target the virus. The results contribute to growing structural insight that will be needed for successful vaccine development against SARS-CoV-2.
A single dose of the flu drug baloxavir marboxil can reduce the spread of the illness within households, new research concludes.
A team led by scientists at Scripps Research has discovered a common molecular feature found in many of the human antibodies that neutralize SARS-CoV-2, the coronavirus that causes COVID-19.
Red blood cells do more than shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens on their surfaces, neutralizing them, and presenting them to immune cells in the spleen and liver.
Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.
Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.
Scientists from the Vaccine and Infectious Disease Organization-International Vaccine Centre at the University of Saskatchewan and Temple University have demonstrated that a Salmonella biofilm protein can cause autoimmune responses and arthritis in animals.
Researchers at the Francis Crick Institute have characterized the structure of the SARS-CoV-2 spike protein as well as its most similar relative in a bat coronavirus. The structures provide clues about how the spike evolved and could help inform vaccine design.
Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection.